COVID-19 vaccine reaches phase-2 trials in China
Share - WeChat

BEIJING - An inactivated COVID-19 vaccine candidate developed by the Institute of Medical Biology under the Chinese Academy of Medical Sciences has entered phase-2 clinical trials in China, the Science and Technology Daily reported Saturday.
The phase-2 trials, which further evaluate the immunogenicity and safety of the vaccine in humans, are conducted in the southwestern province of Yunnan.
So far, five COVID-19 vaccine candidates have been approved for clinical trials in China, accounting for 40 percent of the total vaccines in clinical trials worldwide, according to the Ministry of Science and Technology.
- Chinese scientists lead discovery of parasitic fungus from 100 million years ago
- 110,000th China-Europe freight train exits China
- What they say
- 39th International Travel Expo kicks off in Hong Kong
- Taiwan influencer's livestreaming trip to mainland sparks buzz online, exposes DPP misinformation
- Chinese and EU experts stress ethical use of AI